logo-loader
RNS
viewCircassia Pharmaceuticals PLC

Block listing Interim Review

/**/ sup{font-size:80%} .g{size:595.3pt 841.9pt;margin:2.0cm 2.0cm 2.0cm 2.0cm;}div.g{}p.al{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: center}span.aj{font-size:14.0pt;font-family:"Arial","sans-serif"}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";}span.ah{font-size:10.0pt;font-family:"Arial","sans-serif"}span.ag{font-size:10.0pt;font-family:"Arial","sans-serif"; font-variant:small-caps}p.am{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-bottom:12.0pt;text-autospace:none}span.af{font-size:8.0pt;font-family:"Arial","sans-serif"}p.an{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold} table.ao{width:481.9pt;margin-left:-5.4pt;border-collapse:collapse;border:none}td.ab{width:49.86%;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.ap{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:6.0pt;margin-right:0cm;margin-bottom: 6.0pt;margin-left:0cm}td.aa{width:50.14%;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.z{width:49.86%;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.x{width:50.14%;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}span.y{font-size:10.0pt;font-family:"Arial","sans-serif"; color:black}td.w{width:37.18%;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.v{width:12.68%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.u{width:19.0%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt} td.t{width:8.44%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.s{width:22.7%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.aq{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:6.0pt;margin-right:0cm;margin-bottom: 6.0pt;margin-left:0cm;text-align:justify}span.r{font-size:10.0pt; font-family:"Arial","sans-serif"}span.p{font-family: "Arial","sans-serif"; font-size: 10.0pt; text-decoration: underline}span.o{font-size: 10.0pt;font-family:"Arial","sans-serif"}td.n{border:none}p.ar{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:6.0pt;margin-right:0cm;margin-bottom:6.0pt; margin-left:0cm}td.k{width:49.84%;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.j{width:50.16%;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt} td.i{width:49.84%;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.h{width:50.16%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt} /**/
RNS Number : 1451O
Circassia Pharmaceuticals Plc
30 September 2019
 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

(Note: Italicised terms have the same meaning as given in the Listing Rules.)

Date: 30 September 2019

 

Name of applicant:

Circassia Pharmaceuticals plc

Name of scheme:

Circassia EMI Share Option Scheme

Period of return:

From:

1st July 2019

To:

30th September 2019

Balance of unallotted securities under scheme(s) from previous return:

700,750

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

-

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

-

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

700,750

 

Name of applicant:

Circassia Pharmaceuticals plc

Name of scheme:

Circassia 2007 Unapproved Share Scheme

Period of return:

From:

1st July 2019

To:

30th September 2019

Balance of unallotted securities under scheme(s) from previous return:

203,000

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

-

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

-

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

203,000

 

Name of applicant:

Circassia Pharmaceuticals plc

Name of scheme:

Circassia 2014 Performance Share Plan Scheme

Period of return:

From:

1st July 2019

To:

30th September 2019

Balance of unallotted securities under scheme(s) from previous return:

76,676

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

-

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

-

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

76,676

 

Name of applicant:

Circassia Pharmaceuticals plc

Name of scheme:

Circassia 2015 Performance Share Plan Scheme

Period of return:

From:

1st July 2019

To:

30th September 2019

Balance of unallotted securities under scheme(s) from previous return:

280,612

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

-

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

-

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

280,612

 

 

Name of applicant:

Circassia Pharmaceuticals plc

Name of scheme:

Circassia 2016 Performance Share Plan Scheme

Period of return:

From:

1st July 2019

To:

30th September 2019

Balance of unallotted securities under scheme(s) from previous return:

-

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

930,000

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

(117,929)

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

812,071

 

Name of contact:

Julien Cotta

Telephone number of contact:

01865 405 560

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BLRWGUUUBUPBGUU

Quick facts: Circassia Pharmaceuticals PLC

Price: 17.15

Market: LSE
Market Cap: £64.34 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE